Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics

Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to l-DOPA in the hemi-parkinsonian rat

(2014) Corinne Y. Ostock et al.   BEHAVIOURAL BRAIN RESEARCH

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa

(2014) R. Cilia et al.   BRAIN

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusionvs. oral tablets

(2014) Ahmed A. Othman et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of Levodopa in Patients With Parkinson Disease and Motor Fluctuations Depending on the Presence of Helicobacter pylori Infection

(2014) Ewa Narożańska et al.   CLINICAL NEUROPHARMACOLOGY

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

(2014) Stéphane Palfi et al.   LANCET

Dual effects of l-DOPA on nigral dopaminergic neurons

(2013) Ezia Guatteo et al.   EXPERIMENTAL NEUROLOGY

Motor fluctuations and Helicobacter pylori in Parkinson’s disease

(2013) Karl-Erik Rahne et al.   JOURNAL OF NEUROLOGY

5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease

(2013) Cristina Aureli et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial

(2013) Robert A Hauser et al.   LANCET NEUROLOGY

Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease

(2013) Peter A. LeWitt et al.   MOVEMENT DISORDERS

The role of small intestinal bacterial overgrowth in Parkinson's disease

(2013) Alfonso Fasano et al.   MOVEMENT DISORDERS

Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway

(2013) Mario Riverol et al.   NEUROBIOLOGY OF DISEASE

Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease

(2012) Gabriele Mittermeyer et al.   HUMAN GENE THERAPY

L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease

(2011) Jennifer M. King et al.   LIFE SCIENCES

Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic l-DOPA treatment in a rat model of Parkinson's disease

(2011) Kosuke Ebihara et al.   NEUROSCIENCE LETTERS

The long-duration response to levodopa: Phenomenology, potential mechanisms and clinical implications

(2011) Elise Anderson et al.   PARKINSONISM & RELATED DISORDERS

Factors Associated With Motor Fluctuations and Dyskinesia in Parkinson Disease

(2010) Fabrizio Stocchi et al.   CLINICAL NEUROPHARMACOLOGY

A brief history of levodopa

(2010) Oleh Hornykiewicz   JOURNAL OF NEUROLOGY

Movement chunking during sequence learning is a dopamine-dependant process: a study conducted in Parkinson’s disease

(2010) Pierre-Luc Tremblay et al.   EXPERIMENTAL BRAIN RESEARCH

Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies

(2009) Peter A. LeWitt et al.   MOVEMENT DISORDERS

MAO-B inhibitor know-how: Back to the pharm

(2009) P. A. LeWitt   NEUROLOGY

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

(2008) J. L. Eberling et al.   NEUROLOGY

Levodopa for the Treatment of Parkinson's Disease

(2008) Peter A. LeWitt   NEW ENGLAND JOURNAL OF MEDICINE